Skip to results

Keyword or reference number

Area of interest

Type

Showing 101 to 110 of 345

Guidance and quality standards awaiting development
TitleType
Durvalumab with tremelimumab and transarterial chemoembolisation with or without lenvatinib for treating locally advanced hepatocellular carcinoma PD [ID6527]Technology appraisal guidance
Durvalumab with tremelimumab for treating limited-stage small-cell lung cancer after chemoradiation [ID5097]Technology appraisal guidance
Durvalumab with tremelimumab for treating limited-stage small-cell lung cancer after chemoradiation [ID5097]Technology appraisal guidance
Dusquetide for treating oral mucositis during chemoradiation for head and neck cancer [ID3830]Technology appraisal guidance
Edaravone for treating amyotrophic lateral sclerosis [TSID11869]Technology appraisal guidance
Eflornithine with lomustine for treating anaplastic astrocytoma after radiotherapy and adjuvant temozolomide [TSID10046]Technology appraisal guidance
Elamipretide for treating Barth syndrome in people of any age [ID6545]Technology appraisal guidance
Elexacaftor–tezacaftor–ivacaftor with ivacaftor for treating cystic fibrosis without an F508del mutation and with a mutation in the CFTR gene that is responsive to elexacaftor–tezacaftor–ivacaftor in people aged 6 and over [TSID11847]Technology appraisal guidance
Elinzanetant for treating vasomotor symptoms associated with menopause [ID6359]Technology appraisal guidance
Elinzanetant for treating vasomotor symptoms caused by adjuvant endocrine treatment to prevent or treat hormone-receptor positive breast cancer [ID6544]Technology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All